Results 81 to 90 of about 5,275 (178)

The experiences and perspectives of people with gout on urate self‐monitoring

Health Expectations
Introduction Gout management remains suboptimal despite safe and effective urate‐lowering therapy. Self‐monitoring of urate may improve gout management, however, the acceptability of urate self‐monitoring by people with gout is unknown.
Toni J. F. Michael, Jian S. Chan, Stephen Hughes, Daniel F. B. Wright, Matthew J. Coleshill, Dyfrig A. Hughes, Richard O. Day, Parisa Aslani, Sophie L. Stocker   +8 more
doaj   +1 more source

Surprising safety outcomes of urate-lowering therapy [PDF]

Nature Reviews Rheumatology, 2018
openaire   +2 more sources

Monosodium Urate Crystal Depletion and Bone Erosion Response in Kidney Transplant Recipients With Uncontrolled Gout Treated With Pegloticase: PROTECT Serial Dual-Energy Computed Tomography Findings

Transplantation Direct
Background. Hyperuricemia and gout are associated with poor outcomes in kidney transplant (KT) recipients, including graft failure. The PROspective sTudy of pEglotiCase in Transplant patients (PROTECT) trial showed high urate-lowering efficacy of ...
Nicola Dalbeth, MD, Abdul Abdellatif, MD, John K. Botson, MD, Kenneth G. Saag, MD, Ada Kumar, MD, Lissa Padnick-Silver, PhD, Zana Vranic, PhD, Brad A. Marder, MD, Fabio Becce, MD   +8 more
doaj   +1 more source

Beliefs of rheumatologists and general practitioners on urate lowering therapy: a cross-sectional study. [PDF]

Rheumatol Adv Pract, 2023
Veenstra F, Vriezekolk JE, van den Bemt BJF, Schers HJ, Sloot B, van den Ende CHM, van Herwaarden N, Flendrie M.   +7 more
europepmc   +1 more source

Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England. [PDF]

Rheumatology (Oxford), 2023
Russell MD, Roddy E, Rutherford AI, Ellis B, Norton S, Douiri A, Gulliford MC, Cope AP, Galloway JB.   +8 more
europepmc   +1 more source

Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions. [PDF]

Br J Clin Pharmacol, 2022
Coleshill MJ, Day RO, Tam K, Kouhkamari M, Caillet V, Aung E, Kannangara DRW, Cronin P, Rodgers A, Stocker SL.   +9 more
europepmc   +1 more source

Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry. [PDF]

Sci Rep, 2023
Do H, Choi HJ, Choi B, Son CN, Kim SH, Choi SR, Kim JH, Kim MJ, Shin K, Kim HO, Song R, Lee SW, Ahn JK, Lee SG, Lee CH, Son KM, Moon KW.   +16 more
europepmc   +1 more source

Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study. [PDF]

Rheumatology (Oxford), 2023
Hu S, Sun M, Li M, Xue X, Terkeltaub R, Wang C, Wang M, Lu J, Ran Z, Li H, Ji A, Sun W, Li X, He Y, Liu Z, Zhang H, Wang X, Ji X, Dalbeth N, Li C.   +19 more
europepmc   +1 more source

Initiation of Urate Lowering Therapy (ULT)

The Singapore Family Physician, 2019
Meng Kam Richard Lee, Yee Nah Anita Lim
openaire   +2 more sources

When underlying biology threatens the randomization principle - initial gout flares of urate-lowering therapy. [PDF]

Nat Rev Rheumatol, 2022
Choi HK, Zhang Y, Dalbeth N.
europepmc   +1 more source